欧洲肝脏研究学会肝细胞癌临床实践指南（2018）更新要点解读

鉴于欧洲乃至全球肝细胞癌(HCC)发病率和病死率的不断攀升,增强早期监控力度、提高早期诊断率、精准分期指导个体化治疗是目前HCC管理的关键。2018年4月,欧洲肝脏研究学会(EASL)更新发布了HCC临床实践指南,聚焦HCC的监测、诊断、分期和治疗的相关问题,对HCC分期系统以及各期患者治疗策略的推荐进行全面更新。基于中国原发性肝癌诊疗规范(2017年版)重要观点、最新循证医学证据,笔者对指南更新要点作一解读,旨在为临床决策者对HCC管理指南的灵活应用提供帮助。

Interpretation of essential points of the updates of EASL clinical practice guidelines for management of hepatocellular carcinoma (2018)

Due to increased incidence and mortality rates of hepatocellular carcinoma (HCC), enhancing early detection efforts, improving early diagnosis rates and personalized therapy guided by precise staging are of great importance for management of HCC at present. In April 2018, the European Society for the Study of the Liver (EASL) released the updated clinical practice guidelines for HCC, focusing on HCC monitoring, diagnosis, staging, and treatment related issues, which comprehensively updated the recommendations for the HCC staging system and the treatment strategies for patients in various stages. Based on the main points of the guidelines for the diagnosis and treatment of primary liver cancer in China (2017) and latest evidence-based research resources, the authors interpret the essential points of the updates, so as to provide help for the clinical decision makers to appropriately apply the guidelines for HCC management.